NCT00037817View on ClinicalTrials.gov

Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

May 17, 2002

Primary Completion Date

October 8, 2008

Study Completion Date

November 9, 2009

Conditions
Advanced Esophageal CancersPrimary Small Cell Lung CancersNon-Small-Cell Lung CarcinomaPleural MesotheliomasCancers of Non-thoracic Origin With Metastases to the Lungs or Pleura
Interventions
DRUG

Decitabine

assigned dose level on day 4 and day 10 of each 34 day cycle

BIOLOGICAL

Depsipeptide

assigned dose level on day 4 and day 10 of each 34 day cycle

DRUG

Celecoxib

400mg PO BID on days 4 through 34 of each cycle

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00037817 - Phase I Study of Gene Induction Mediated by Sequential Decitabine/Depsipeptide Infusion With or Without Concurrent Celecoxib in Subjects With Pulmonary and Pleural Malignancies | Biotech Hunter | Biotech Hunter